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Abstract
It is generally accepted that early detection of breast cancer has
great impact on patient survival, emphasizing the importance of
early diagnosis. In a widely recognized model of breast cancer
development, tumor cells progress through chronological and well
defined stages. However, the molecular basis of disease
progression in breast cancer remains poorly understood. High-
throughput molecular profiling techniques are excellent tools for
the study of complex molecular alterations. By accurately mapping
changes in the genome and subsequent biological/molecular
pathways, the chances of finding potential novel treatment targets
as well as intervention strategies are enhanced, and ultimately lives
can be saved. This review provides a brief summary of recent
progress in identifying molecular markers for invasiveness in early
breast lesions.
Introduction
The commonly accepted model for cancer development is
that cancer cells, over a long period of time, acquire the
hallmarks of malignancy (e.g. oncogene activation and loss of
tumor suppressor gene function) [1]. The vast majority of
breast neoplasia arises in the ductal epithelial cells, and is
generally believed to be a chronological progression through
defined clinical and pathological stages. These stages start
with premalignant atypical ductal hyperplasia (ADH), which
may progress to preinvasive ductal carcinoma in situ (DCIS),
followed by a possible progression to invasive ductal
carcinoma (IDC) and culmination in metastatic disease [2].
Atypical lobular hyperplasia and lobular carcinoma in situ,
comprising a small proportion of all breast neoplasia, are
breast cancer risk factors and constitute nonmandatory
precursors for the successive development of invasive
carcinoma in either breast, of either ductal or lobular type [3].
Alternative pathways to development of invasive breast
cancer have been suggested (for review, see the report by
Simpson and coworkers [4]), emphasizing the importance of
studying benign proliferative and preinvasive breast lesions in
relation to invasive disease. Finding molecular markers of
invasive or metastatic potential in early stage lesions would
therefore have considerable impact on breast cancer
diagnosis, treatment and prognosis.
Although comparative genomic hybridization (CGH) and loss
of heterozygosity have provided compelling evidence that
ADH and DCIS are precursors to IDC, the molecular basis of
progression in early stages of breast cancer remains poorly
understood [2]. This is partly due to tumor heterogeneity, with
intra-tumor as well as inter-tumor variation based on, for
instance, varying grades of mitotic activity, cellular differen-
tiation and presence of normal and inflammatory cells.
There is evidence to support the notion that breast cancer
arises from mutated mammary stem/progenitor cells, which
have been termed ‘breast cancer stem cells’ because of their
exclusive ability to maintain tumor formation and growth, as
reviewed by Behbod and coworkers [5]. Al-Hajj and
colleagues [6] were the first group to identify this population
of highly tumorigenic cells in human breast tumor isolates.
When transplanted into NOD/SCID mice, as few as 100 of
these cells were able to form tumors.
High throughput genome-wide array based techniques such
as array-CGH and transcriptional profiling provide an oppor-
tunity to discover genes and/or pathways that are specifically
activated or inactivated during tumor progression. This review
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focuses on the efforts that have been made to find molecular
markers for invasiveness in early breast lesions and to find
metastasis-associated gene signatures that are present in
early tumorigenesis. A glossary of terms used is provided in
Table 1.
Tissue heterogeneity
Tumors as well as precancerous lesions are heterogeneous
cell populations that harbor normal stromal and inflammatory
cells in addition to cancer cells. The presence of these
nonmalignant cells could mask the detection of genetic and
transcriptional alterations in cancer cells. However, recent
advances in cell isolation techniques, reviewed by Eltoum and
coworkers [7], permit precise isolation of separate cell
populations for individual analysis.
Precancerous or early stage breast cancer lesions are
diminutive, and the amount of material obtained from these
small specimens is often far less than is required for genome-
wide analyses. This problem can be addressed by the use of
amplification techniques such as degenerate oligonucleotide
primed polymerase chain reaction, which permits relatively
uniform amplification of the entire genome. Similarly, RNA can
be linearly amplified, for instance with T7 polymerase, for
global gene expression studies. However, these methods of
amplification can result in misrepresentation of certain genes
or genomic regions.
During the past few years the role of the cellular micro-
environment in tumorigenesis has become an intense area of
research. This is partly due to studies demonstrating that
genetic abnormalities occur not only in cancer cells but also
in stromal cells [8]. Moreover, Kurose and coworkers [9]
demonstrated high frequencies of somatic mutations in TP53
(encoding tumor protein p53) and PTEN (encoding
phosphate and tensin homolog) in both breast neoplastic
epithelium and stroma. Ding and colleagues [10] recently
evaluated the level of EZH2 protein (a transcriptional
repressor that is involved in controlling cellular memory) in
breast tissue samples (normal, ADH and DCIS lesions).
EZH2 expression was elevated in ADH compared with
normal epithelium, and was even higher in DCIS. Of interest,
histologically normal lobules adjacent to ADH and DCIS
exhibited a significantly increased number of cells expressing
EZH2 when compared with distant normal lobules, indicating
that elevated levels of EZH2 protein expression can detect a
precancerous state in morphologically normal breast
epithelium. In an elegant study, Allinen and coworkers [11]
described comprehensive transcriptional profiles of each
individual cell type composing normal breast tissue and in
situ and invasive breast carcinoma (including epithelial cells,
leukocytes, myofibroblasts and myoepithelial cells, and endo-
thelial and stromal cells) using a sequential isolation protocol
for each cell population combined with serial analysis of gene
expression (SAGE). They determined that extensive
transcriptional changes occur in all cell types during cancer
progression, but genomic alterations were detected only in
epithelial cancer cells. Molecular characterization of each
constituent cell type will contribute to our understanding of
the role played by these cells in breast tumorigenesis, and
may also provide new molecular targets for breast cancer
intervention and treatment.
Genome-wide molecular profiling applications
The analysis of gene expression profiles can give insights into
changes in biochemical pathways that occur during malignant
Table 1
Glossary of terms used in the present review
Term Description
Microarray Microscope slide or chip with immobilized probes, usually cDNA, BAC, or oligo probes
cDNA Complementary DNA: a DNA that is complementary to a given RNA, which serves as a template for synthesis of the DNA in the 
presence of reverse transcriptase. When printed on microarray slides, they are usually 0.5-2 kilobases (kb)
BAC Bacterial artificial chromosome: a DNA construct, based on a fertility plasmid, used for transforming and cloning in bacteria, 
usually Escherichia coli. Its usual insert size is 150 kb, with a range from 100 to 300 kb
Oligo Oligonucleotide: a relatively short single-stranded nucleic acid chain, usually 20-80 base pairs
Gene expression  Global analysis of transcribed RNA in a tissue of interest. Usually based on the cohybridization of differentially labeled test and 
profiling  reference cDNAs to probes on microarray slides
SAGE Serial analysis of gene expression: generates a library of expressed genes by taking a raw count of sequence tags, each 
representing a transcript in the RNA population
CGH Comparative genomic hybridization: comparative hybridization of differentially labeled DNA of interest (e.g. tumor) and a 
reference (any genomic DNA) to normal metaphase chromosomes
Array-CGH Array-based CGH: comparative hybridization of differentially labeled DNA of interest (e.g. tumor) and a reference (any genomic 
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transformation and cancer progression. Transcriptional profiles
corresponding to thousands of genes can be established
simultaneously by global profiling techniques (i.e. microarrays
and SAGE). Microarray techniques are based on the hybridi-
zation of cDNA samples to immobilized probes on microarray
slides, whereas the SAGE method generates a library of
expressed genes by taking a raw count of sequence tags,
each representing a transcript in the RNA population.
Absolute quantification of the expressed genes permits the
creation of gene expression profiles that can be compared
with libraries from other cell or tissue types [12]. A major
advantage of SAGE over microarrays is that it does not
require any prior knowledge of the sequences to be analyzed.
However, microarrays are more amenable to the analysis of
large sample sets. Of interest, a study comparing SAGE and
microarray data [13] revealed a good correlation between the
two techniques.
Array-based CGH can be used to identify high-resolution
global genomic changes acquired during cancer progression.
In array-CGH differentially labelled test DNA (e.g. tumor) and
normal control DNA is co-hybridized onto a representation of
the genome, consisting of a multitude of printed spots of
target DNA. Arrays made from cDNA have been used most
often for this purpose [14], but the use of cDNA clones as
targets for genomic DNA is hampered by the suboptimal
hybridization of genetic material present in introns in the
genomic DNA but absent in cDNAs. Bacterial artificial
chromosome (BAC) arrays, on the other hand, utilize
segments of human genomic DNA as hybridization targets;
32k tiling BAC arrays provide an average resolution of about
80 kilobases [15]. High-density oligonucleotide arrays have a
higher resolution of regions of interest than do BAC arrays,
but they are usually nontiling [16]. Custom-made arrays are
commercially available from several vendors, and these
enable individual probe design of single exon resolution.
Gene expression and breast cancer
classification
Gene expression profiling has proven to be a useful and
reliable tool for classifying breast cancers into subgroups that
reflect different histopathological characteristics as well as
differential prognostic outcome. It has been suggested that
estrogen receptor negative and positive breast cancers can
be subdivided into Her-2 positive basal-epithelial like, normal
breast-like and luminal-like [17]. The potentially different
origins of the tumor cells may signify distinct pathways of
tumorigenesis and differences in the clinical course of the
disease.
Germ-line mutations in the BRCA1 and  BRCA2 genes
together account for a significant portion of hereditary breast
cancers. They have been shown to leave a characteristic
imprint on the panel of genes expressed by the tumors [18],
with  BRCA1-dependent tumors exhibiting a transcriptional
profile similar to the basal subtype of tumors [19]. These
findings suggest that the cellular origin of BRCA1 and
BRCA2 mutation positive tumors may differ, or that these
tumors traverse down separate pathways in their progression
toward malignancy [18]. Furthermore, the molecular sub-
classification of non-BRCA1/2 familial breast cancers into
homogeneous subgroups underscores the potential differen-
ces in cellular origin and/or disease progression due to the
presence of multiple diverse underlying genetic alterations,
which is reflected in the phenotype of the tumors [20].
Transcriptional profiling of premalignant and
early stage breast cancer
Using SAGE analysis on a small set of normal breast tissues,
DCIS and IDC tumors, Abba and coworkers [21] detected
significant changes that occur during the course of breast
cancer progression. They were also able to identify genes
and gene families commonly deregulated across samples
within each specific stage in the transition from benign breast
tissue to IDC. By comparing differential gene expression
profiles established by cDNA microarrays between normal
cells, primary invasive carcinoma and metastatic cells, Mimori
and coworkers [22] were able to detect genes directly
associated with each tumor stage in tumor development and
gave clues to the comprehensive identification of metastasis-
related genes in clinical breast cancer biopsies. In contrast,
using the combination of laser capture microdissection and
DNA microarrays to generate gene expression profiles of
premalignant, preinvasive and invasive stages of human
breast cancer, Ma and colleagues [23] discovered extensive
similarities across the distinct stages of progression,
suggesting that transcriptional alterations granting the
potential for invasive growth are already present in the
preinvasive stages. Interestingly, they found that different
histological grades were associated with distinct gene
expression signatures, and that a subset of genes associated
with high histological grade was correlated with the transition
from preinvasive to invasive growth. In accordance with this,
Weigelt and coworkers [24] showed that distant metastases
exhibit both the same breast cancer subtype and trans-
criptional signature as their primary tumors, which was
interpreted by some as the capacity to metastasize being an
inherent feature of most breast cancers.
Several studies attempting to classify breast tumors into
good or poor prognosis categories have been reported.
Strikingly, very few genes are found in common among these
independent gene signatures. Although this may in part be
explained by the use of different microarray platforms, among
other differences, it has become increasingly evident that
further data from well designed trials are needed to identify
key determinants before these diagnostic techniques may be
introduced into the clinical setting [25]. Nonetheless, these
studies have shown us that stratification of breast tumors by
clinicopathological and transcriptional profiles before
determination of prognostic and treatment predictive genetic
signatures may be the most effective approach to achieve
Available online http://breast-cancer-research.com/content/8/4/213improved and tailored clinical management. Importantly,
histological grade, largely coinciding with hormone receptor
status, strongly reflects the magnitude and type of genetic
aberrations in invasive breast cancers (for review, see the
report by Simpson and coworkers [4]), emphasizing the
correlation between genotype and phenotype during disease
progression. These findings stress the need to combine
histopathological parameters with molecular profiling
techniques for translation into clinical practice.
Genetic aberrations in premalignant and
early stage breast lesions
A multitude of molecular studies have been performed in
DCIS and IDC tumors with the common goal of identifying
genes involved in the initiation of sporadic disease, and
investigation of the link between in situ and invasive
carcinoma. Lukas and coworkers [26] found that the
frequency of TP53 mutations in DCIS was similar to that
found in invasive tumors. Moreover, the in situ and invasive
components exhibited identical mutations, reinforcing the
clonal relationship between in situ and invasive lesions. Upon
investigation of HER-2 in a cohort of women diagnosed with
benign breast disease, Stark and colleagues [27] concluded
that women with benign breast biopsies exhibiting both
HER-2 amplification and a proliferative histopathological
lesion may be at substantially increased risk for developing
subsequent breast cancer. Overexpression of the HER-2/neu
protein in otherwise benign biopsies may indicate a further
increase in risk. Moreover, several studies have analyzed the
identity and distribution of chromosomal alterations in ductal
hyperplasias and in situ and invasive carcinomas. In general,
more advanced tumors exhibit more genetic changes,
although many of the changes are already present in in situ
carcinomas or even in ductal hyperplasia, suggesting a
progressive accumulation of genomic aberrations.
Combining molecular approaches
The combination of array-CGH and gene expression profiling
is probably one of the most reliable and comprehensive ways
to find new marker genes for breast cancer progression and
metastasis. In a recent study conducted by Yao and
coworkers [28], including DCIS, IDC and lymph node meta-
stases, the authors identified 49 minimal commonly amplified
regions, including known (1q, 8q24, 11q13, 17q21-q23 and
20q13) and previously uncharacterized regions (12p13 and
16p13). They confirmed that the overall frequency of copy
number aberrations was higher in invasive tumors than in
DCIS, with several aberrations occurring only in invasive
cancer. By combining array-CGH and SAGE data they were
able to distinguish a number of putative breast cancer onco-
genes.
Ultimately, the genome-wide search for genes and bio-
chemical pathways or networks causing phenotypic changes
during breast tumorigenesis will require the integration of
both genomic, transcriptional, and proteomic approaches.
Finding pathways and networks that are involved in cancer
progression when interpreting data from genome-wide
analyses can be tremendously complex, and therefore gene
ontology tools can be invaluable. Validation experiments of
the results from genome-wide screens must be performed
using molecular techniques such as immunohistochemistry,
fluorescent  in situ hybridization, or chromogenic in situ
hybridization. For such purposes the use of tissue microarray
technology has proven useful. This technique allows for
simultaneous analysis of several hundreds of samples in a
single staining experiment [29]. Also, it has become
increasingly evident that epigenetic changes must be taken
into consideration in the investigation of breast cancer
aetiology. Yang and coworkers [30] showed that methylation
changes occur not only in tumor cells but also in normal
breast tissue as far as 4 cm away from primary tumor sites.
Functional studies using cell line or animal models to
investigate the role of individual genes or gene products may
shed further light on the events that underlie malignant
transformation and disease progression.
Conclusion
We conclude that high throughput genomic and gene
expression analyses have proven to be valuable tools for
identifying putative molecular markers for tumor development
and metastatic potential. It is important to verify these findings
with other molecular techniques as well as in large clinical
trials. Moreover, functional validation of causal relationships
between genetic alterations and disease aetiology would
increase our biological understanding of breast tumori-
genesis, in addition to providing molecular targets for
intervention, diagnosis and treatment.
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